Literature DB >> 6325937

Development of homozygosity for chromosome 11p markers in Wilms' tumour.

S H Orkin, D S Goldman, S E Sallan.   

Abstract

Somatic alterations in the genome are found in many human tumours. Chromosome rearrangements or base substitutions that activate cellular oncogenes appear to act dominantly. In contrast, recessive alleles apparently contribute to childhood retinoblastoma, as homozygosity (or hemizygosity ) for chromosome 13 is often established in tumours, by either mitotic nondisjunction or recombination. Parallels exist between retinoblastoma and childhood Wilms' tumour (WT). Retinoblastoma is often inherited and accompanied by a deletion of chromosome 13 (band q14), while WT is occasionally associated with aniridia and deletion of chromosome 11 band p13. Most Wilms' tumours are sporadic and not accompanied by these findings, although interstitial deletion of chromosome 11 in tumour, but not normal, cells has been reported. In view of these parallels, we compared constitutional and tumour DNAs from WT patients by using chromosome 11p DNA probes. We report here that although heterozygosity in constitutional DNAs was often preserved in tumour DNAs, one case developed homozygosity for chromosome 11p markers in tumour cells, implying the involvement of chromosomal events in revealing a recessive WT locus. This observation suggests the action of such general mechanisms in a tumour other than retinoblastoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325937     DOI: 10.1038/309172a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  100 in total

1.  X rays induce interallelic homologous recombination at the human thymidine kinase gene.

Authors:  M B Benjamin; J B Little
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

2.  Oncogenic role of miR-483-3p at the IGF2/483 locus.

Authors:  Angelo Veronese; Laura Lupini; Jessica Consiglio; Rosa Visone; Manuela Ferracin; Francesca Fornari; Nicola Zanesi; Hansjuerg Alder; Gemma D'Elia; Laura Gramantieri; Luigi Bolondi; Giovanni Lanza; Patrizia Querzoli; Adriano Angioni; Carlo M Croce; Massimo Negrini
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

3.  Numerical aberrations of chromosomes 11 and 17 in colorectal adenocarcinomas.

Authors:  Y Tagawa; T Sawai; T Nakagoe; M Morinaga; T Yasutake; H Ayabe; M Tomita
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

4.  Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families.

Authors:  B Newman; M A Austin; M Lee; M C King
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

5.  A system for assaying homologous recombination at the endogenous human thymidine kinase gene.

Authors:  M B Benjamin; H Potter; D W Yandell; J B Little
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

6.  Constitutional extra chromosomal element in a family with Wilms' tumor.

Authors:  S Kakati; H Xiao; S Y Siddiqui; C Sreekantaiah; H U Weier; D M Green; J E Fisher; J E Allen
Journal:  Hum Genet       Date:  1991-06       Impact factor: 4.132

7.  Linkage analysis of a DNA marker localized to 20p12 and multiple endocrine neoplasia type 2A.

Authors:  P J Goodfellow; B N White; J J Holden; A M Duncan; E V Sears; H S Wang; L Berlin; K K Kidd; N E Simpson
Journal:  Am J Hum Genet       Date:  1985-09       Impact factor: 11.025

8.  Measurements of the frequency of human erythrocytes with gene expression loss phenotypes at the glycophorin A locus.

Authors:  R G Langlois; W L Bigbee; R H Jensen
Journal:  Hum Genet       Date:  1986-12       Impact factor: 4.132

9.  novH: differential expression in developing kidney and Wilm's tumors.

Authors:  G Chevalier; H Yeger; C Martinerie; M Laurent; J Alami; P N Schofield; B Perbal
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

Review 10.  Genetic alterations in primary breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.